174 related articles for article (PubMed ID: 24898091)
21. Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.
Ehlers MR; Nepom GT
Rev Diabet Stud; 2012; 9(4):359-71. PubMed ID: 23804273
[TBL] [Abstract][Full Text] [Related]
22. IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localization.
Li CR; Deiro MF; Godebu E; Bradley LM
J Autoimmun; 2011 Nov; 37(3):217-27. PubMed ID: 21745722
[TBL] [Abstract][Full Text] [Related]
23. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
Bell CJ; Sun Y; Nowak UM; Clark J; Howlett S; Pekalski ML; Yang X; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Umana P; Klein C; Hosse RJ; Wicker LS; Peterson LB
J Autoimmun; 2015 Jan; 56():66-80. PubMed ID: 25457307
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
Long SA; Rieck M; Sanda S; Bollyky JB; Samuels PL; Goland R; Ahmann A; Rabinovitch A; Aggarwal S; Phippard D; Turka LA; Ehlers MR; Bianchine PJ; Boyle KD; Adah SA; Bluestone JA; Buckner JH; Greenbaum CJ;
Diabetes; 2012 Sep; 61(9):2340-8. PubMed ID: 22721971
[TBL] [Abstract][Full Text] [Related]
25. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
26. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients.
Zhao C; Chu Y; Liang Z; Zhang B; Wang X; Jing X; Hao M; Wang Y; An J; Zhang X; Sun L; Chen J
BMC Immunol; 2019 Sep; 20(1):32. PubMed ID: 31484501
[TBL] [Abstract][Full Text] [Related]
27. CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms.
Yuan X; Dong Y; Tsurushita N; Tso JY; Fu W
JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367461
[TBL] [Abstract][Full Text] [Related]
28. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.
Long SA; Cerosaletti K; Bollyky PL; Tatum M; Shilling H; Zhang S; Zhang ZY; Pihoker C; Sanda S; Greenbaum C; Buckner JH
Diabetes; 2010 Feb; 59(2):407-15. PubMed ID: 19875613
[TBL] [Abstract][Full Text] [Related]
29. Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers.
Izquierdo C; Ortiz AZ; Presa M; Malo S; Montoya A; Garabatos N; Mora C; Verdaguer J; Stratmann T
Sci Rep; 2018 May; 8(1):8106. PubMed ID: 29802270
[TBL] [Abstract][Full Text] [Related]
30. Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.
Jaberi-Douraki M; Pietropaolo M; Khadra A
J Theor Biol; 2015 Oct; 383():93-105. PubMed ID: 26271890
[TBL] [Abstract][Full Text] [Related]
31. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.
Cerosaletti K; Schneider A; Schwedhelm K; Frank I; Tatum M; Wei S; Whalen E; Greenbaum C; Kita M; Buckner J; Long SA
PLoS One; 2013; 8(12):e83811. PubMed ID: 24376757
[TBL] [Abstract][Full Text] [Related]
32. Effect of redox status of peripheral blood on immune signature of circulating regulatory and cytotoxic T cells in streptozotocin induced rodent model of type I diabetes.
Anupam K; Kaushal J; Prabhakar N; Bhatnagar A
Immunobiology; 2018 Oct; 223(10):586-597. PubMed ID: 30017263
[TBL] [Abstract][Full Text] [Related]
33. Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.
Manirarora JN; Wei CH
J Immunol; 2015 Dec; 195(11):5203-14. PubMed ID: 26482409
[TBL] [Abstract][Full Text] [Related]
34. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro.
Yates J; Rovis F; Mitchell P; Afzali B; Tsang J; Garin M; Lechler RI; Lombardi G; Garden OA
Int Immunol; 2007 Jun; 19(6):785-99. PubMed ID: 17545278
[TBL] [Abstract][Full Text] [Related]
35. Cytokines and T regulatory cells in the pathogenesis of type 1 diabetes.
Kikodze N; Pantsulaia I; Rekhviashvili Kh; Iobadze M; Dzhakhutashvili N; Pantsulaia N; Kukuladze N; Bikashvili N; Metreveli D; Chikovani T
Georgian Med News; 2013 Sep; (222):29-35. PubMed ID: 24099812
[TBL] [Abstract][Full Text] [Related]
36. T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients.
Parackova Z; Kayserova J; Danova K; Sismova K; Dudkova E; Sumnik Z; Kolouskova S; Lebl J; Stechova K; Sediva A
Autoimmunity; 2016 Dec; 49(8):523-531. PubMed ID: 27560779
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-35 administration counteracts established murine type 1 diabetes--possible involvement of regulatory T cells.
Singh K; Kadesjö E; Lindroos J; Hjort M; Lundberg M; Espes D; Carlsson PO; Sandler S; Thorvaldson L
Sci Rep; 2015 Jul; 5():12633. PubMed ID: 26224624
[TBL] [Abstract][Full Text] [Related]
38. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes.
Baeyens A; Pérol L; Fourcade G; Cagnard N; Carpentier W; Woytschak J; Boyman O; Hartemann A; Piaggio E
Diabetes; 2013 Sep; 62(9):3120-31. PubMed ID: 23670972
[TBL] [Abstract][Full Text] [Related]
39. Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?
Visperas A; Vignali DA
J Immunol; 2016 Nov; 197(10):3762-3770. PubMed ID: 27815439
[TBL] [Abstract][Full Text] [Related]
40. Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study.
Barde F; Lorenzon R; Vicaut E; Rivière S; Cacoub P; Cacciatore C; Rosenzwajg M; Daguenel-Nguyen A; Fain O; Klatzmann D; Mekinian A
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38580347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
